Background: Mantle-cell lymphoma (MCL) is genetically characterized by the translocation t(ll;14)(ql3;q32) leading to an overexpression of cyclin-Dl, but additional chromosomal abnormalities appear to be required for MCL pathogenesis.
Introduction
Mantle-cell lymphoma (MCL) is a specific subtype of non-Hodgkin's lymphoma (NHL) derived from naive CD5+ B-cells of the follicle mantle zone and characterized by distinct clinical, morphological and genetic features [1, 2] . The cytogenetic hallmark of MCL is the translocation t(ll;14)(ql3;q32) [3, 4] . This aberration leads to a rearrangement of the BCL-1 (Ilql3) and IgH (14q32) loci resulting in the deregulation of the cyclin Dl gene (CCNDl) [5] [6] [7] . The overexpression of CCND1 at the mRNA and protein levels is highly characteristic of MCL [6] [7] [8] [9] [10] . Since the cyclin Dl protein is a key member of the Gl-S checkpoint of the cell cycle, the CCNDl deregulation by the t(ll;14)(ql3;q32) is considered crucial for MCL pathogenesis. However, the transforming potential of cyclin Dl appears to be less pronounced than that of other proto-oncogenes [11] . In keeping with this is the observation that transgenic mice overexpressing cyclin Dl do not spontaneously develop lymphoma and that other oncogenic factors such as c-myc are necessary for tumor formation [12, 13] . Therefore, additional genetic events appear to be required in the malignant transformation.
The involvement of tumor suppressor genes has been described in subsets of MCL. Aggressive or blastoid MCL variants have been shown to harbor alterations of TP53 and CDKN2 and frequently display tetraploid chromosome clones [14] [15] [16] [17] [18] [19] . Additional aberrations have been revealed in MCL by chromosome banding analyses [20] [21] [22] , and the use of molecular cytogenetic techniques has refined the affected regions [23] . Deletions involving bands Uq22-q23 are among the commonly observed aberrations in MCL (Bentz et al., submitted) [23] , and are also frequent in other B-cell lymphoproliferative disorders [24] . In the current study we analyzed 81 MCL for llq deletions with the aim to identify the minimally deleted segment likely harboring a tumor suppressor gene involved in the pathogenesis of MCL.
Patients and methods
Tumor samples were prepared from 81 patients with MCL and molecular cytogenetic analysis was performed as previously described [25] . Briefly, cells from infiltrated tissues were obtained by mechanical disaggregation and pepsin digestion followed by centrifugation onto glass slides. In leukemic cases mononuclear cells were obtained from peripheral blood samples by ficoll density gradient centrifugation, hypotonic treatment and fixation with methanol/acetic acid. The specimens of the 37 MCL with 1 lq deletions were derived from lymph node (b = 20), peripheral blood (b = 13). spleen (b = 1). tonsil (b = 1). stomach (h -1) or conjunctiva (b -1). Diagnoses were based on morphological and immunophenotypical analyses [1] . Among the 37 MCL with llq deletions the t(ll;14)(ql3:q32) corresponding to a CCNDl/IgH rearrangement was present in all 35 cases tested by our interphase FISH assay [26] .
Molecular cytogenetic analysis was performed by dual color FISH with a physically mapped probe set of YAC clones spanning bands 1 Iql4 to 1 Iq24 as previously described (for details of the probe set see Figure 1 ) [24, 27] . Control probes to assure a high hybridization efficiency and cut-off levels for the diagnosis of deletions were applied as described [24] . To screen for llq deletions, Alu-PCR products 4) were included in a previous study [24] . The minimal deletion region lost in all MCL analyzed (dark gray) is delineated by PAC ATM-1 and -2 located in the centromenc part of YAC 80lei I. The centromenc border of the minimal deletion is defined by MCL numbers 8 and 29 while the telomeric border is defined by MCL number 33 exhibiting loss of PAC ATM-1 and -2 and retention of two signals for YAC 80lell.
M C L (n=37)
derived from YAC 755bll and YAC 80leIl (obtained from the CEPH library; Genethon, Fondation Jean Dausset, Paris, France) were used in all 81 tumor samples. YAC 755bll maps to a previously established minimal deletion region in B-cell chronic lymphocytic leukemia (B-CLL) [24, 26] , and YAC 801ell contains the ATM gene which is disrupted inT-prolymphocytic leukemia (T-PLL) [28. 29] . The extent of the deletions was determined by systematic hybridization of probes from the YAC contig (see Figure 1) . PAC probes specific for ATM (PAC ATM-1, LLNLP704G18220Q19; PAC ATM-2, LLNLP704O01298QI9) and for YAC 755bll (PAC 755bll; LLNLP704H1725Q13) were identified from a human PAC library (segments RPCI 1, 3-_5) [30] , obtained from the Resource Center/Reference Library of the German Human Genome Project by hybridization with cDNA clone pCEV7-9 [31] and Alu-PCR products derived from YAC 755bll, respectively. The ATM exon content of the PACs was determined by PCR analysis [28] . ATM mutation analyses were performed by single-strand conformation polymorphism (SSCP) analyses and direct sequencing after RT-PCR as previously described [28, 32] .
Results and discussion
Screening for llq deletions was initially performed by interphase FISH with YAC 755bll and YAC 801ell which map to previously identified deletion regions in neoplasms of the lymphoid system [24, 28, 29] . Deletions involving at least one of these probes were observed in 36 of the 81 MCL studied (46%). No biallelic deletion was found. The percentage of cells carrying a deletion ranged from 13%-98.5% (median 84%). The 46% incidence of llq loss in MCL is remarkably higher than assumed from smaller series [23] , and exceeds the frequency of llq deletions in B-CLL [26] . The high incidence of Ilq22-q23 deletion together with the frequent observation of 13ql4 deletion in MCL and B-CLL [33] , suggests common genetic mechanisms in the pathogenesis of the two diseases despite their different clinical behavior.
The extent of the llq deletions was determined by FISH with a probe set consisting of a YAC contig spanning bands Ilql4 to Ilq24 (Figure 1 ). Among the 36 MCL with llq deletions detected, a minimal deletion region affecting YAC 801ell was established. The genomic segment corresponding to this YAC probe was lost in all MCL cases with llq deletions studied and in one of the MCL was the sole fragment lost (number 8 in Figure 1 ). YAC 801ell is 1.2 Mb in size and contains the genomic region of the ATM gene.
To further narrow the minimal deletion segment and to test whether ATM or an adjacent locus was affected by the llq deletions in MCL we isolated PACs containing ATM coding sequences (PAC ATM-1 and -2) and a PAC from the YAC 755bll region (PAC 755bl 1). Exons 4-49 and exons 25-65 of the ATM gene were contained in PAC ATM-1 and PAC ATM-2, respectively, as detected by PCR analysis. Forty MCL cases showing no aberration upon initial FISH screening with YACs 80lei 1 and 755bll were subjected to analysis with these PAC probes. One MCL (number 33, Figure 1 ) was found to carry a deletion of the genomic region corresponding to PAC ATM-1 and -2. Subsequent analysis with YAC probes showed that this MCL carried a deletion extending in centromeric direction (see Figure 1) . Since PAC ATM-1 and -2 are located in the centromeric end of MCL number 14 carried a deletion of one ATM allele (see Figure 1) and a splice site mutation in the remaining allele resulting in skipping of exon 59. MCL number 38 had two different mutations, one affecting each A TM allele. For details of the mutation analysis methodology and results see also ref. [32] YAC 801ell this further narrowed the minimal deletion region lost in all MCL with llq deletions analyzed to the centromeric portion of YAC 80lei 1 where the ATM gene resides (see Figure 1) . Interestingly, our data are at variance to a very recent report by Monni et al., who analyzed 20 MCL with 1 lq deletions by FISH with YAC probes [34] . In this study one MCL with an isolated deletion of the genomic region recognized by YAC 755bll located 2-3 Mb telomeric of ATM was identified, while in all other cases larger deletions also affecting ATM were found.
The assumption that ATM and not another gene in Ilq22-q23 is affected by the llq deletions in MCL is supported by data from mutation analyses [32] . In two MCL cases from our series alterations within the ATM coding region were found by RT-PCR followed by SSCP analyses and confirmed by direct sequencing. MCL number 14, which showed a monoallelic deletion involving Ilq22-q23 (see Figure 1) , carried a splice site mutation leading to the loss of exon 59 in the ATM mRNA (see Table 1 ). This mutation disrupts the functionally important phosphatidylinositol-3-kinase domain of the ATM protein. Another MCL tumor from our series, which showed no abnormality in Ilq22-q23 by FISH, was found to carry two different mutations, each affecting one of the two ATM alleles (see Table 1 ).
Disruption of both ATM alleles in accordance with the two-hit model of tumor suppressor gene inactivation was previously demonstrated in T-PLL [28, 29, 35] . In addition, recent studies showed loss of ATM protein expression and mutational disruption of ATM in B-CLL which suggests a pathogenic role also in B-cell malignancies [32, [36] [37] [38] . In the current study, the identification of an Ilq22-q23 minimal deletion region in MCL which specifically affects ATM together with the observation of mutations in the coding sequence, suggest a role of ATM as a tumor suppressor gene in the pathogenesis of MCL.
Although the function of the ATM gene product is not fully established, studies of ataxia-telangiectasia (A-T) cell lines and ATM deficient mice have shown that ATM is a key regulator in response to DNA strand brakes induced by mutagenic agents or physiological processes such as VDJ recombination [39] . A-T patients carry germ-line mutations of both ATM alleles and frequently develop T-cell leukemia characterized by aberrant rear- Figure 2 . Hypothesis of the genetic events underlying the pathogenesis of MCL by analogy to the abnormalities observed in T-PLL of A-T patients. In A-T patients the following sequence of events is well established [40] : 1) the disruption of both ATM alleles leading to a faulty surveillance of DNA integrity is already present in the germline; 2) the illegitimate T-cell receptor rearrangement with the TCLl oncogene by the t(14;14) leads to a benign expansion of aT-cell clone; 3) the acquisition of additional chromosome aberrations finally results in overt T-cell leukemia. Similar events appear to occur in T-PLL of non-A-T individuals with the difference that the inactivation of ATM is acquired by somatic mutation [28, 29] Based on the current data one may speculate that a similar sequence of events could occur in MCL:
MCL
The somatic ATM inactivation by deletion and mutation results in a faulty surveillance of DNA integrity. This could allow the illegitimate IgH rearrangement with the CCNDl oncogene by the translocation t(ll;14)(ql3;q32). The subsequent acquisition of additional genetic aberrations could result in overt lymphoma.
rangement of T-cell receptor genes (TCR) with protooncogenes [40] . Similar rearrangements are found in sporadic T-PLL which is characterized by somatic ATM inactivation [28, 29, 35] . In this context it is interesting to note that the hallmark of MCL is the rearrangement of the IgH locus with the oncogene CCNDl as a result of illegitimate VDJ recombination. Based on the current results this aberrant VDJ recombination in MCL and the subsequent acquisition of additional genetic changes leading to complex karyotypes could result from a faulty surveillance of the genomic integrity by loss of the ATM gene product (see Figure 2) .
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